1870 Glaukos

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Retrieved on: 
Thursday, December 14, 2023
Pharmaceutical, Optical, General Health, Health, FDA, Medical Devices, Health Technology, Clinical Trials, NDA, Webcast, OAG, Eye, Acquisition, NYSE, Intraocular pressure, Safety, Food, Ocular hypertension, Travoprost, Corporation, IOP, Patient, Glaucoma, Nature, BID, U.S. FDA, Idose, Uveitis, Telecanthus, New Drug Application, Field line, Conference, MD, Timolol, Mercury (element), GKOS, OHT, Retina, Pharmaceutical industry, Medical device, 1870 Glaukos

“The FDA approval of iDose TR represents a significant milestone for Glaukos following an extensive pioneering journey since the inception of the original idea nearly 15 years ago.

Key Points: 
  • “The FDA approval of iDose TR represents a significant milestone for Glaukos following an extensive pioneering journey since the inception of the original idea nearly 15 years ago.
  • The FDA approval and Phase 3 data referenced below is for the slow-release iDose TR model, consistent with the company’s NDA submission and commercialization plans.
  • Alongside the iDose TR approval announcement, Glaukos is proud to introduce the iDose Your Dose Initiative.
  • ET (5:30 a.m. PT) to discuss the FDA approval of iDose TR.

Glaukos Announces Participation in Stifel Healthcare Conference

Retrieved on: 
Tuesday, November 7, 2023
Medical Devices, Health, Surgery, Pharmaceutical, Optical, Biotechnology, Corporation, Conference, NYSE, Retina, 1870 Glaukos, Glaucoma, GKOS, Pharmaceutical industry, Online shopping

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 10:55 a.m.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 10:55 a.m.
  • ET in New York City.
  • A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com .

Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)

Retrieved on: 
Monday, June 5, 2023
Health, Health Technology, Clinical Trials, Pharmaceutical, Optical, Biotechnology, GKOS, Glaucoma, Food, NDA, Corneal topography, Retina, Keratoconus, Corporation, Patient, EPI, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Safety, Pharmaceutical industry, 1870 Glaukos

“We appreciate the commitment and dedication of the clinical investigators, who played a vital role in helping to achieve this enrollment milestone ahead of our original timing expectations.

Key Points: 
  • “We appreciate the commitment and dedication of the clinical investigators, who played a vital role in helping to achieve this enrollment milestone ahead of our original timing expectations.
  • The study eyes were randomized in a 2:1 ratio to receive Epioxa therapy or placebo and sham procedure control treatment.
  • Results from this second Phase 3 confirmatory pivotal trial together with the already-completed first Phase 3 pivotal trial are expected to support Glaukos’ targeted NDA submission for Epioxa by the end of 2024.
  • As a reminder, the U.S. FDA has confirmed Glaukos’ first Phase 3 pivotal trial for Epioxa, which met the pre-specified primary efficacy endpoint, would be adequate to support the submission and review of an eventual NDA, in conjunction with this second Phase 3 trial.

Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 13, 2023
Research, SG, Patient, IOP, Webcast, 1870 Glaukos, Partnership, News, Optometry, American Academy, OMNI, MIGS, Telecanthus, Cleveland, Growth, Alcon, Cleveland Clinic, Publication, Literature, Cryptocurrency, Video game, Pharmaceutical industry

“Our improved fourth quarter 2022 financial results reflected the impact of the operating expense rationalization initiative we began in the third quarter.

Key Points: 
  • “Our improved fourth quarter 2022 financial results reflected the impact of the operating expense rationalization initiative we began in the third quarter.
  • This will allow us to further exploit the operating leverage we flexed in the fourth quarter.”
    Revenue for the fourth quarter of 2022 was $20.5 million, an increase of $5.9 million, or 40%, compared to the fourth quarter of 2021.
  • Gross profit for the fourth quarter of 2022 was $16.9 million compared to $12.7 million for the fourth quarter of 2021.
  • Operating expenses as a percentage of revenues decreased from 187% in the fourth quarter of 2021 to 165% in the fourth quarter of 2022.

Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Retrieved on: 
Tuesday, January 10, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Ilut, New Drug Application, Duane syndrome, Standard of care, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Keratoconus, Corporation, Safety, Dermis, FDA, Pilocarpine, Glaucoma, Eyelid, NYSE, NDA, Food, Patient, GKOS, DED, Eye, Retina, BID, Pharmaceutical industry, 1870 Glaukos

“These clinical updates represent meaningful milestones for two of our key Corneal Health pipeline programs and we look forward to continuing to advance both of these important programs forward in 2023,” said Thomas Burns, Glaukos chairman and chief executive officer.

Key Points: 
  • “These clinical updates represent meaningful milestones for two of our key Corneal Health pipeline programs and we look forward to continuing to advance both of these important programs forward in 2023,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • Glaukos plans to randomize approximately 290 subjects in this trial and is targeting enrollment completion by the end of 2023.
  • Glaukos also announced promising topline results from its Phase 2a first-in-human clinical trial for GLK-301 (iLution – Dry Eye Disease (DED)) for the signs and symptoms of DED.
  • Based on these encouraging observations, Glaukos plans to advance GLK-301 into a Phase 2b clinical trial targeted to begin in 2023.

Glaukos Announces the Release of its 2021 Sustainability Report

Retrieved on: 
Wednesday, April 20, 2022
Pharmaceutical, Health, Optical, U.S. Securities and Exchange Commission, ISO, Security (finance), Annual report, GKOS, Glaucoma surgery, Sustainability reporting, ESG, Goal, Patient, DEI, Corporation, Glaucoma, Sustainability, NYSE, Certification, MIGS, Time, Retina, Pharmaceutical industry, Risk management, 1870 Glaukos

I am proud to issue our third annual Sustainability Report reflecting our commitment to continuous improvement as responsible corporate citizens, said Thomas Burns, Glaukos chairman and chief executive officer.

Key Points: 
  • I am proud to issue our third annual Sustainability Report reflecting our commitment to continuous improvement as responsible corporate citizens, said Thomas Burns, Glaukos chairman and chief executive officer.
  • Over the course of 2021, we continued to invest significant time and resources into better understanding what drives sustainability at Glaukos.
  • For additional information and highlights, please see Glaukos 2021 Sustainability Report, which can be found on the companys website here .
  • These potential risks and uncertainties include, without limitation, our ability to achieve the sustainability targets identified in the sustainability report.

Beyond Blindness Marks Milestone Year with 60th Anniversary Gala

Retrieved on: 
Tuesday, February 8, 2022
Diamond, Paralympic Games, Visual impairment, Growth, Wine, Humble Bundle, Social, Early childhood intervention, Family support, Severe cognitive impairment, Sale, 1870 Glaukos, COVID-19, Decade, Topical steroid withdrawal, Population, Founder, Gold, History, Optimism, Entertainment, Management, Pharmaceutical industry

SANTA ANA, Calif., Feb. 8, 2022 /PRNewswire-PRWeb/ -- In recognition of its milestone year, Beyond Blindness is pleased to announce the 60th Anniversary Gala taking place Saturday, Feb. 26 at Marconi Automotive Museum in Tustin.

Key Points: 
  • SANTA ANA, Calif., Feb. 8, 2022 /PRNewswire-PRWeb/ -- In recognition of its milestone year, Beyond Blindness is pleased to announce the 60th Anniversary Gala taking place Saturday, Feb. 26 at Marconi Automotive Museum in Tustin.
  • Dining in the dark, the gala's signature element, will allow guests to personally experience the challenge of vision loss.
  • Proceeds from the 60th Anniversary Gala directly support Beyond Blindness' Early Intervention, Education + Enrichment, and Family Support Services for children with visual impairments and other disabilities.
  • This year marks a celebration of past, present, and future for Beyond Blindness.

Glaukos Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Friday, November 19, 2021
Surgery, Medical Devices, Health, Pharmaceutical, Optical, 1870 Glaukos, Conference, Technology, Cross-link, MIGS, NYSE, Retina, Investor, EST, Corporation, Glaucoma surgery, Glaucoma, Cornea, GKOS, Pharmaceutical industry, Animal

Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Key Points: 
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.
  • In corneal health, Glaukos proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions.
  • Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)

Retrieved on: 
Wednesday, November 10, 2021
Health, Securities Exchange Act of 1934, Safety, Intraocular pressure, Intellectual property, OMNI, Glaucoma, Industry, Private Securities Litigation Reform Act, RCT, Pressure, 1870 Glaukos, Clinical trial, U.S. Securities and Exchange Commission, TM, Entrepreneurship, CEO, Technology, IDE, Food, Exocrine gland, Trial of the century, COVID-19, Food and Drug Administration Amendments Act of 2007, Securities Act of 1933, Forward-looking statement, Eyelid, Regulation, Trabecular meshwork, Severe cognitive impairment, MGD, Company, GLOBE, Eye, Jumpstart Our Business Startups Act, Time, Trauma, IOP, MIGS, Nasdaq, Patient, FDA, Surgeon, Adult, Pharmaceutical industry, Dentistry, Medical device, Surveying

The devices that will be evaluated in the study are the higher volume OMNI (Sight Sciences) and the iStent Inject Canal Implant (Glaukos).

Key Points: 
  • The devices that will be evaluated in the study are the higher volume OMNI (Sight Sciences) and the iStent Inject Canal Implant (Glaukos).
  • Sight Sciences is conducting this canal viscodilation alone IDE trial, which is believed to be necessary to support a premarket notification to the FDA seeking clearance for use to perform canal viscodilation alone procedures in adults with POAG.
  • This trial is the next step in our path to set the clinical standards of canal viscodilation as a MIGS procedure for POAG.
  • The forward-looking statements are subject to and involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements.

AEON Biopharma Announces the Appointment of Alex Wilson as General Counsel

Retrieved on: 
Wednesday, August 11, 2021
AEON, Industry, Business development, UCLA School of Law, Toxin (comics), Gastroparesis, Patient, Union, Acetylcholine, Physician, United Kingdom, Denervation, Brigham Young University, Arbutus Biopharma, Forward-looking statement, European Union, Clostridium botulinum, 1870 Glaukos, Migraine, General counsel, Associate, Relaxation, EMA, Terminology, SEC, FDA, GLOBE, Marketing, Economics, Neurology, Pharmaceutical industry

NEWPORT BEACH, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, today announced the appointment of Alex Wilson to the role of General Counsel.

Key Points: 
  • NEWPORT BEACH, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, today announced the appointment of Alex Wilson to the role of General Counsel.
  • I am proud to join AEON at this exciting time in the companys history.
  • Prior to joining AEON, Alex served as Associate General Counsel, Business Development & Sustainability at Glaukos Corporation.
  • Previously, Alex worked as a corporate attorney in the Newport Beach office of OMelveny & Myers.